Physician

Akanksha Agrawal, M.D.

According to 2025 Medicare claims, Akanksha Agrawal, M.D. (NPI: 1730563628) practices advanced heart failure and transplant cardiology in the Palm Bay-Melbourne-Titusville, FL market, with the plurality of this provider's patient population coming from Brevard, FL. This provider's primary affiliated billing organization is FLORIDA HOSPITAL MEDICAL GROUP INC (NPI: 1225034234; TIN: 593214635) and primary practice location at 32803-1248.

Agrawal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 200 traditional Medicare patients, billed 990 HCPCS/CPT codes, and received $91,544 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,031 prescription claims across 124 beneficiaries totaling $914,414 in drug costs, led by Jardiance (Empagliflozin). DME data shows 444 claims. Open Payments data shows 20 records totaling $1,293. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $5,402 to $914,414. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	79	300	$28,125
2024	200	990	$91,544

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	26	142	$5,402
2016	69	314	$20,493
2017	80	513	$30,195
2018	28	323	$18,318
2019	31	94	$14,344
2020	15	56	$7,080
2021	N/R	16	$2,781
2022	N/R	N/R	N/R
2023	58	160	$37,395
2024	124	1,031	$914,414

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	13	$163
2024	37	444	$18,187

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	43	50	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	60	121	$133
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	62	253	$90
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	48	50	$51
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	32	36	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	50	3,010	$57,550
Entresto	Sacubitril/Valsartan	28	1,590	$33,543
Sirolimus	Sirolimus	33	2,820	$21,281
Tacrolimus	Tacrolimus	37	2,941	$6,706
Mycophenolate Mofetil	Mycophenolate Mofetil	35	3,012	$5,407

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	23	$10,898
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	13	135	$1,768
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	13	91	$1,675
J7517	Mycophenolate mofetil, oral, 250 mg	N	11	73	$1,617
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	81	$1,481

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$1,293	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Akanksha Agrawal, M.D.?

Tedicare shows public-source Medicare data for Akanksha Agrawal, M.D. (NPI 1730563628), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Akanksha Agrawal, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Akanksha Agrawal, M.D.?

Akanksha Agrawal, M.D. is linked to FLORIDA HOSPITAL MEDICAL GROUP INC (billing NPI 1225034234) in the available physician profile data.

Does Akanksha Agrawal, M.D. have Open Payments data?

Akanksha Agrawal, M.D. has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.